Potency of SiRNA Versus ShRNA Mediated Knockdown in Vivo
Overview
Pharmacy
Affiliations
The intracellular delivery of small interfering RNA (siRNA) is a therapeutic strategy to transiently block gene expression. Two silencing RNA strategies utilize either synthetic double stranded RNA or plasmid DNA encoding a short hairpin RNA (shRNA). In the present study, we have quantitatively compared the potency of siRNA (siLuc1) and shRNA (pShagLuc) mediated knockdown of luciferase expression in vivo using hydrodynamic dosing and bioluminescence imaging (BLI). Following hydrodynamic coadministration of siLuc1 or pShagLuc with a plasmid encoding luciferase (pGL3), mice were analyzed for transgene expression by BLI. The knockdown of luciferase expression by siLuc1 or pShagLuc was observed at 3 h and persisted for 3 days. The potency of siLuc1 and pShagLuc was equivalent with maximal effect at 10 microg coadministered with 1 microg of pGL3 resulting in >80% knockdown. Combined dosing of siLuc1 and pShagluc (5 microg each) with 1 microg of pGL3 resulted in >99% knockdown. Analysis of the data established that shRNA was significantly more potent than siRNA at mediating knockdown when compared on a mole basis. The combination of hydrodynamic dosing and BLI to measure siRNA or shRNA mediated knockdown of luciferase provide an attractive in vivo quantitative method to test formulations that target the liver.
Novel gene manipulation approaches to unlock the existing bottlenecks of CAR-NK cell therapy.
Dehghan F, Metanat Y, Askarizadeh M, Ahmadi E, Moradi V Front Cell Dev Biol. 2025; 12:1511931.
PMID: 40007761 PMC: 11850336. DOI: 10.3389/fcell.2024.1511931.
Optimal delivery of RNA interference by viral vectors for cancer therapy.
Wong B, Birtch R, Rezaei R, Jamieson T, Crupi M, Diallo J Mol Ther. 2023; 31(11):3127-3145.
PMID: 37735876 PMC: 10638062. DOI: 10.1016/j.ymthe.2023.09.012.
Isenmann M, Stoddart M, Schmelzeisen R, Gross C, Della Bella E, Rothweiler R Micromachines (Basel). 2023; 14(7).
PMID: 37512632 PMC: 10383872. DOI: 10.3390/mi14071321.
Campeiro J, Dam W, Hayashi M, van den Born J Pharmaceutics. 2023; 15(6).
PMID: 37376025 PMC: 10302291. DOI: 10.3390/pharmaceutics15061576.
Tumor Radiosensitization by Gene Electrotransfer-Mediated Double Targeting of Tumor Vasculature.
Savarin M, Znidar K, Sersa G, Komel T, Cemazar M, Kamensek U Int J Mol Sci. 2023; 24(3).
PMID: 36769077 PMC: 9917180. DOI: 10.3390/ijms24032755.